The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -44.92 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 5.09 — flag raised, worth a closer lookWatch
- Earnings quality 17/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as KYNTRA BIO, INC. reports it. History and quarterly detail are in the app.
- Drug Product Revenue$5.8M
- Development And Other Revenue$592K
Leadership changes
From KYNTRA BIO, INC.'s own filings, the day they're filed.
- Michael Kauffman · director · appointmenteff. 2025-06-04
- Aoife Brennan · Directors · departureeff. 2025-06-04
- Suzanne Blaug · Directors · departureeff. 2024-09-30
Latest filings
- 8-K · Company announcement2026-08-31
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-09
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about KYNTRA BIO, INC., every answer cited to the official filings🔒
- The Intelligence Brief — added when KYNTRA BIO, INC.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.